Morgan Stanley
HOWL icon

Morgan Stanley’s Werewolf Therapeutics HOWL Stock Holding History

Morgan Stanley’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.1K Sell
33,799
-12,203
-27% -$8.36K ﹤0.01% 6612
2025
Q4 		$29.1K Buy
46,002
+26,750
+139% +$32.5K ﹤0.01% 6583
2025
Q3 		$37.9K Sell
19,252
-7,948
-29% -$10.9K ﹤0.01% 6495
2025
Q2 		$29.6K Sell
27,200
-80,627
-75% -$83K ﹤0.01% 6517
2025
Q1 		$105K Sell
107,827
-30,315
-22% -$39.7K ﹤0.01% 5988
2024
Q4 		$204K Buy
138,142
+19,102
+16% +$38.9K ﹤0.01% 5776
2024
Q3 		$252K Buy
119,040
+70,028
+143% +$159K ﹤0.01% 5663
2024
Q2 		$120K Buy
49,012
+28,433
+138% +$137K ﹤0.01% 5901
2024
Q1 		$133K Buy
20,579
+19,379
+1,615% +$113K ﹤0.01% 5876
2023
Q4 		$4.63K Sell
1,200
-1,300
-52% -$3.32K ﹤0.01% 7019
2023
Q3 		$5.35K Hold
2,500
– – ﹤0.01% 6901
2023
Q2 		$7.63K Hold
2,500
– – ﹤0.01% 6897
2023
Q1 		$6.5K Sell
2,500
-12
-0.5% -$36 ﹤0.01% 7000
2022
Q4 		$5.15K Sell
2,512
-7,975
-76% -$20.9K ﹤0.01% 7138
2022
Q3 		$47K Sell
10,487
-11,799
-53% -$64.1K ﹤0.01% 6436
2022
Q2 		$91K Buy
22,286
+14,656
+192% +$66.9K ﹤0.01% 6324
2022
Q1 		$33K Sell
7,630
-433
-5% -$3.03K ﹤0.01% 6899
2021
Q4 		$96K Buy
8,063
+6,549
+433% +$98.8K ﹤0.01% 6466
2021
Q3 		$26K Buy
1,514
+1,247
+467% +$21.3K ﹤0.01% 6992
2021
Q2 		$5K Buy
+267
New +$3.66K ﹤0.01% 7378

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley's HOWL Position: Q1 2026 in Review

Morgan Stanley reduced its Werewolf Therapeutics (HOWL) stake by 27% in Q1 2026, selling an estimated $8.36K and leaving 33,799 shares worth $28.1K. The position accounts for ﹤0.01% of the portfolio, ranked #6612.

Morgan Stanley first reported a position in HOWL in Q2 2021 and has held it in 20 quarters since. The position peaked at $252K in Q3 2024. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.

  • Morgan Stanley held 33,799 shares of Werewolf Therapeutics worth $28.1K as of Q1 2026.
  • Morgan Stanley sold 12,203 Werewolf Therapeutics shares in Q1 2026, an estimated $8.36K.
  • Werewolf Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6612 holding.
  • Morgan Stanley first reported a position in Werewolf Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Morgan Stanley's Werewolf Therapeutics position peaked at $252K in Q3 2024.
  • 48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.